AUA 2018: Assessing the Under-Estimation of Nodal Tumour Burden by 68ga-PSMA and 11c-Choline PET/CT Scan in Patients Treated with Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer

San Francisco, CA (UroToday.com) PET scan (using multiple tracers, including Choline, PSMA, FDG) has become increasingly utilized in the management of prostate cancer, particularly for the identification of small volume recurrent disease that may not be identified on traditional imaging, such as CT scans or bone scans. Its role is rapidly developing, and the “oligometastatic” prostate cancer disease space continues to expand. 

Many of these patients identified with small volume recurrence in nodal tissue are now being offered salvage lymphadenectomy as a treatment option – at the very least, it may delay time to hormone therapy. However, as with all new technologies, with increased utilization users have noted potential discrepancies between PET findings and clinical findings. 

In this series, the authors of multiple institutions with significant experience with salvage lymphadenectomy based on PSMA PET imaging retrospectively compare PET imaging findings vs. final surgical pathology in 525 men who received extended salvage lymphadenectomy for oligometastatic disease. All patients were diagnosed with PET/CT scan using either 11C-choline (n=356; 68%) or 68Ga-PSMA (n=169; 32%). They hypothesized that PET imaging underestimated the volume of metastatic disease. As such, their primary outcome was the number of underestimated nodes: number of positive lymph nodes at SLND minus number of positive spots at PET/CT scan. The variables they assessed for association with underestimation were: the number of positive spots on PET/CT scan, PSA level at the time of SLND, PET/CT tracer (11C-choline vs. 68Ga-PSMA), and the number of nodes removed.

Of the 525 men, the number of positive spots on pre-operative PET/CT scan was 1 in 364 men (52%), 2 in 151 men (22%), 3 in 101 men (15%), and ≥4 in 79 men (11%) patients, respectively. Interestingly, most studies would consider those with 4+ nodes outside the oligometastatic space, so the fact that they got an SLND is indicative of the aggressive nature of these groups. This is highlighted by the fact that ~60% had pT3 disease, 38% were Gleason 8-10, 34% had positive surgical margins, and 20% were pN1 at the time of RP. 28% of patients had detectable PSA post-RP. 

The median number of lymph nodes removed at SLND was 19 (IQR: 10, 31). The time from RP to SLND was 28 months on average, so approximately 2 years. 

The number of positive nodes was 0 in 110 men (16%), 1 in 165 men (24%), 2 in 82 men (12%), and ≥3 in 338 (49%) patients, respectively. Median under-estimation of tumour burden was 1 (IQR: -1, 4). 

At multivariable analysis, accounting for the other variables mentioned (modality of PET scan, PSA level at time of SLND, and number of nodes removed at SLND), the number of positive spots at PET/CT scan was a significant predictor of under-estimation of tumour burden (linear coefficient: 0.23; p=0.02). 

The interaction test for the hypothesis that under-estimation of tumour burden varies by PET/CT tracer was statistically significant (p<0.0001). Under-estimation was relevant with both tracers, but it was more evident with 11C-Choline as compared to 68Ga-PSMA. 

Ultimately, the more spots present on the PET scan, the higher the chance of finding higher volume disease at the time of SLND. While the authors conclude that this supports extended SLND, I would argue that it would imply that higher volume disease patients may not benefit from SLND as they may have disease elsewhere that is not being removed by SLND – which is why many of these patients with 4+ nodes maybe should not have been considered oligometastatic!

This obviously warrants further discussion, but it is reassuring to know that PET scans with 1-2 spots are less likely to be underestimating the volume of disease.

Some questions that came up during the discussion:
1. Was there are a difference in patients who did not have a node dissection initially (pNx) vs. those who were pN1? The authors state there was no significant difference. 
2. The authors made it clear during the discussion that this should be taken in the context of clinical data, not in isolation – PET scan still has value, just not in isolation!


Presented by: Nicola Fossati, MD
Co-Authors: Nazareno Suardi, Giorgio Gandaglia, Carlo Andrea Bravi, Milan, Italy, Matteo Soligo, Jeffrey R. Karnes, Rochester, MN, Maximilian Schmautz, Axel Heidenreich, Cologne, Germany, Annika Herlemann, Christian Gratzke, Christian Stief, Munich, Germany, Antonino Battaglia, Wouter Everaerts, Steven Joniau, Hendrik Van Poppel, Leuven, Belgium, Almut Kalz, Daniar Osmonov, Klaus-Peter Juenemann, Campus Kiel, Germany, Nieroshan Rajarubendra, Inderbir S. Gill, Los Angeles, CA, Shahrokh F. Shariat, Vienna, Austria, Alexander Mottrie, Melle, Belgium, Francesco Montorsi, Alberto Briganti, Milan, Italy

Written by: Thenappan Chandrasekar, MD, Clinical Fellow, University of Toronto, | twitter: @tchandra_uromd at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe